Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orit Bar-Am

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Neuroscience Letters|January 21, 2004
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegilineOrit Bar Am, Tamar Amit, Moussa B H Youdim
Journal of Neurochemistry|July 20, 2007
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitroOrit Bar-Am, Tamar Amit, Moussa B H Youdim
Journal of Neural Transmission (Vienna, Austria : 1996)|March 2, 2011
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa YoudimOrly Weinreb, Silvia Mandel, Orit Bar-Am, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|April 11, 2015
Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targetsOrit Bar-Am, Tamar Amit, Moussa B Youdim, et al.
Acta Biomaterialia|April 8, 2023
Methacrylated fibrinogen hydrogels for 3D cell culture and deliveryHaneen Simaan-Yameen, Orit Bar-Am, Galit Saar, et al.
Current Drug Targets|January 28, 2012
Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatmentOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
International Review of Neurobiology|October 6, 2011
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitorOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
British Journal of Pharmacology|September 3, 2015
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's diseaseOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
Annals of the New York Academy of Sciences|December 14, 2007
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapyOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
Biomacromolecules|September 22, 2025
Evaluating Cross-Linking Efficiency and Cytocompatibility of Three Commonly Used Photoinitiators across Different Cell-Compatible Hydrogel PlatformsAya Gavish Moscovitz, Haneen Simaan Yameen, Orit Bar-Am, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Neuroscience Letters|January 21, 2004
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegilineOrit Bar Am, Tamar Amit, Moussa B H Youdim
Journal of Neurochemistry|July 20, 2007
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitroOrit Bar-Am, Tamar Amit, Moussa B H Youdim
Journal of Neural Transmission (Vienna, Austria : 1996)|March 2, 2011
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa YoudimOrly Weinreb, Silvia Mandel, Orit Bar-Am, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|April 11, 2015
Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targetsOrit Bar-Am, Tamar Amit, Moussa B Youdim, et al.
Acta Biomaterialia|April 8, 2023
Methacrylated fibrinogen hydrogels for 3D cell culture and deliveryHaneen Simaan-Yameen, Orit Bar-Am, Galit Saar, et al.
Current Drug Targets|January 28, 2012
Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatmentOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
International Review of Neurobiology|October 6, 2011
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitorOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
British Journal of Pharmacology|September 3, 2015
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's diseaseOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
Annals of the New York Academy of Sciences|December 14, 2007
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapyOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
Biomacromolecules|September 22, 2025
Evaluating Cross-Linking Efficiency and Cytocompatibility of Three Commonly Used Photoinitiators across Different Cell-Compatible Hydrogel PlatformsAya Gavish Moscovitz, Haneen Simaan Yameen, Orit Bar-Am, et al.
Pageof 7